AA
RAPT

ALPS Advisors’s RAPT Therapeutics RAPT Stock Holding History

ALPS Advisors’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,032
Closed -$218K – 992
2024
Q1 		$218K Buy
3,032
+130
+4% +$18.1K ﹤0.01% 960
2023
Q4 		$577K Sell
2,902
-269
-8% -$33.3K ﹤0.01% 584
2023
Q3 		$422K Buy
3,171
+15
+0.5% +$2.45K ﹤0.01% 619
2023
Q2 		$472K Buy
3,156
+361
+13% +$56.2K ﹤0.01% 623
2023
Q1 		$410K Sell
2,795
-81
-3% -$16.4K ﹤0.01% 611
2022
Q4 		$456K Buy
2,876
+853
+42% +$137K ﹤0.01% 608
2022
Q3 		$389K Sell
2,023
-176
-8% -$33.3K ﹤0.01% 663
2022
Q2 		$321K Sell
2,199
-1,600
-42% -$213K ﹤0.01% 748
2022
Q1 		$668K Sell
3,799
-475
-11% -$89.7K 0.01% 370
2021
Q4 		$1.26M Sell
4,274
-243
-5% -$65K 0.01% 331
2021
Q3 		$1.12M Buy
4,517
+400
+10% +$106K 0.01% 380
2021
Q2 		$1.05M Buy
+4,117
New +$769K 0.01% 399

Other funds holding RAPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

ALPS Advisors's RAPT Position: Q2 2024 in Review

ALPS Advisors sold out of RAPT Therapeutics (RAPT) in Q2 2024, closing a stake of 3,032 shares — an estimated $218K sold.

ALPS Advisors first reported a position in RAPT in Q2 2021 and held it in 12 quarters. The position peaked at $1.26M in Q4 2021. 103 funds tracked by Wall St. Rank hold RAPT as of Q2 2024.

  • ALPS Advisors reported no remaining RAPT Therapeutics position as of Q2 2024 after selling out during the quarter.
  • ALPS Advisors sold 3,032 RAPT Therapeutics shares in Q2 2024, an estimated $218K.
  • ALPS Advisors first reported a position in RAPT Therapeutics in Q2 2021 and held it in 12 quarters.
  • ALPS Advisors's RAPT Therapeutics position peaked at $1.26M in Q4 2021.
  • 103 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q2 2024.

Based on ALPS Advisors's 13F filing for Q2 2024, filed 13 Aug 2024.